These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28054139)

  • 1. [Local ablative radiotherapy of oligometastatic colorectal cancer].
    Petersen C; Gauer T
    Radiologe; 2017 Feb; 57(2):105-110. PubMed ID: 28054139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
    Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
    Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83-100 Gy in five fractions.
    Takeda A; Sanuki N; Tsurugai Y; Oku Y; Aoki Y
    J Radiat Res; 2016 Jul; 57(4):400-5. PubMed ID: 26983981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer.
    Takeda A; Sanuki N; Kunieda E
    World J Gastroenterol; 2014 Apr; 20(15):4220-9. PubMed ID: 24764660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.
    Niazi T; Elakshar S; Stroian G
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):351-358. PubMed ID: 29979320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer.
    Wild AT; Yamada Y
    Visc Med; 2017 Mar; 33(1):54-61. PubMed ID: 28612018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
    Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
    BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy.
    Franzese C; Comito T; Toska E; Tozzi A; Clerici E; De Rose F; Franceschini D; Navarria P; Reggiori G; Tomatis S; Scorsetti M
    Radiother Oncol; 2019 Apr; 133():220-226. PubMed ID: 30414754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review.
    Kobiela J; Spychalski P; Marvaso G; Ciardo D; Dell'Acqua V; Kraja F; Błażyńska-Spychalska A; Łachiński AJ; Surgo A; Glynne-Jones R; Jereczek-Fossa BA
    Crit Rev Oncol Hematol; 2018 Sep; 129():91-101. PubMed ID: 30097241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease.
    Ahmed KA; Torres-Roca JF
    Cancer Control; 2016 Jan; 23(1):21-9. PubMed ID: 27009453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer.
    Seo YS; Kim MS; Yoo HJ; Jang WI
    World J Gastroenterol; 2014 Feb; 20(8):2005-13. PubMed ID: 24587675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer.
    Sheikh S; Chen H; Sahgal A; Poon I; Erler D; Badellino S; Dagan R; Foote MC; Louie AV; Redmond KJ; Ricardi U; Biswas T
    Radiother Oncol; 2022 Feb; 167():187-194. PubMed ID: 34952002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploratory Analysis on Overall Survival after Either Surgery or Stereotactic Radiotherapy for Lung Oligometastases from Colorectal Cancer.
    Filippi AR; Guerrera F; Badellino S; Ceccarelli M; Castiglione A; Guarneri A; Spadi R; Racca P; Ciccone G; Ricardi U; Ruffini E
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):505-12. PubMed ID: 26899780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management.
    Robin TP; Raben D; Schefter TE
    Semin Radiat Oncol; 2018 Oct; 28(4):288-294. PubMed ID: 30309639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligometastatic Colorectal Cancer: A Review of Definitions and Patient Selection for Local Therapies.
    Miller ED; Hitchcock KE; Romesser PB
    J Gastrointest Cancer; 2023 Dec; 54(4):1116-1127. PubMed ID: 36652155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer.
    Pasqualetti F; Montrone S; Vivaldi C; Zani M; Fedele D; Fornaro L; Pasqualetti G; Salvatore L; Manfredi B; Laliscia C; Coraggio G; Gonnelli A; Loupakis F; Masi G; Sainato A; Monzani F; Falcone A; Paiar F
    Anticancer Res; 2017 Jan; 37(1):315-319. PubMed ID: 28011508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer.
    Guerrero E; Ahmed M
    Lung Cancer; 2016 Feb; 92():22-8. PubMed ID: 26775592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11).
    Park HJ; Chang AR; Seo Y; Cho CK; Jang WI; Kim MS; Choi C
    Anticancer Res; 2015 Sep; 35(9):5103-10. PubMed ID: 26254414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.